Company news
Oryzon Genomics SA news in 2026
Oryzon Genomics SA's news releases, calls and decks from 2026, newest first.
Oryzon Genomics S A to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
November 4, 2026
Oryzon Genomics S A announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
November 3, 2026
Oryzon Genomics S A to participate in upcoming events in November
October 28, 2026
Oryzon Genomics S A further strengthens vafidemstat’s patent portfolio with new decisions to grant
October 15, 2026
ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid Syndrome
September 29, 2026
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
September 28, 2026
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
August 31, 2026
Oryzon Genomics S A reports financial results and corporate update for half year ended June 30th, 2026
July 27, 2026
ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026
July 27, 2026
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
July 8, 2026
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
July 1, 2026
Oryzon Genomics S A raises €12 million and signs a financing agreement with COFIDES to strengthen its balance sheet and accelerate its clinical programs
July 1, 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
June 11, 2026
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
June 2, 2026
Oryzon Genomics S A initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential thrombocythemia
June 2, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
May 13, 2026
ORYZON to Participate in Upcoming Events in May and June
April 29, 2026
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
March 25, 2026
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
March 23, 2026
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
March 12, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
February 27, 2026
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
February 24, 2026
ORYZON to Participate in Upcoming Events in February and March
February 19, 2026
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
February 12, 2026
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
February 9, 2026
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
February 2, 2026
ORYZON to Participate in Upcoming Events in January
January 8, 2026
Decks in 2026
- Investor Presentation (March 2026)
Investor deck · 43 slides · March 2026